Document is current
Any future updates will be listed below
-
Authors
Li, Chen https://orcid.org/0000-0002-6423-6325
Ferro, Ana https://orcid.org/0000-0003-4470-079X
Mhatre, Shivani K.
Lu, Danny
Lawrance, Marcus
Li, Xiao
Li, Shi
Allen, Simon
Desai, Jayesh
Fakih, Marwan
Cecchini, Michael
Pedersen, Katrina S.
Kim, Tae You
Reyes-Rivera, Irmarie
Segal, Neil H.
Lenain, Christelle
-
Funding
Funding for this research was provided by:
This study was sponsored by F. Hoffmann–La Roche Ltd. Sanofi S.A. provided drug supply under an agreement between F. Hoffmann–La Roche Ltd and Sanofi S.A.
- License Information
-
More Information
Article History
Received: 12 August 2021
Accepted: 29 June 2022
First Online: 15 July 2022
Competing interests
: C.Li, A.F., S.K.M., D.L., L.M., S.L., S.A., I.R.R. and C.Lenain are employees of Hoffmann-La Roche Ltd., the company that funded the study. M.F. has received honoraria from Amgen, is an advisor/consultant for Amgen, Array BioPharma, Bayer, GlaxoSmithKline, HalioDx, Incyte, Mirati, Pfizer, Seattle Genetics, Taiho and Zhuhai Yufan Biotech, is a speaker for Amgen and Guardant360 and received institution research funding Amgen, AstraZeneca and Novartis. M.C. has received honoraria from Eisai Co., Agios Pharmaceuticals and AstraZeneca and travel/accommodation/expenses from Genentech/Roche and is receiving research support as part of the Yale Cancer Center Calabresi Immuno-oncology Training Program supported by the National Cancer Institute of the National Institute of Health under Award Number K12 CA215110. All other authors have no competing interests to declare.
